Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of infliximab on B-cell maturation in granulomatous diseases
NL-OMON41509Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Apr 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of infliximab in sarcoidosis and Crohn's disease (2 cohorts), sponsored by Erasmus MC. Primary endpoint: Objective-related endpoint. Started Apr 2014; status: active, not recruiting.
02
Drugs
infliximab
03
Conditions
sarcoidosisCrohn's disease
Beyond the preview
Go deeper on NL-OMON41509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41509.